We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

68 hedge funds and large institutions have $913M invested in Ambrx Biopharma Inc in 2023 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

278% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 9

100% more funds holding in top 10

Funds holding in top 10: 3 → 6 (+3)

61% more capital invested

Capital invested by funds: $568M → $913M (+$345M)

55% more funds holding

Funds holding: 44 → 68 (+24)

46% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 13

26% more call options, than puts

Call options by funds: $4.72M | Put options by funds: $3.74M

Holders
68
Holders Change
+24
Holders Change %
+54.55%
% of All Funds
0.99%
Holding in Top 10
6
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
34
Increased
19
Reduced
13
Closed
9
Calls
$4.72M
Puts
$3.74M
Net Calls
+$974K
Net Calls Change
-$11.9M

Top Buyers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
+$42.2M
2
NI
Nextech Invest
Switzerland
+$35.6M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$24.5M
4
LGM
Logos Global Management
California
+$22.6M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$15.9M

Top Sellers

Rank Fund Capital Flow
1
CC
Commodore Capital
New York
-$40.5M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$23.5M
3
Holocene Advisors
Holocene Advisors
New York
-$5.6M
4
ECM
ExodusPoint Capital Management
New York
-$4.01M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$3.26M
Name Holding Trade Value Shares
Change 		Change in
Stake
AllianceBernstein
26
AllianceBernstein
Tennessee
$3.68M +$2.4M +211,068 +446%
MIM
27
Monashee Investment Management
Massachusetts
$2.95M +$1.56M +137,500 +196%
HS
28
HighVista Strategies
Massachusetts
$2.89M +$107K +9,421 +5%
Barclays
29
Barclays
United Kingdom
$2.85M +$2.27M +199,950 New
ECM
30
ExodusPoint Capital Management
New York
$2.01M -$4.01M -352,551 -71%
TD Asset Management
31
TD Asset Management
Ontario, Canada
$2M +$339K +29,800 +27%
SC
32
Stempoint Capital
New York
$1.8M +$1.43M +126,101 New
LIP
33
Lighthouse Investment Partners
Florida
$1.27M +$1.01M +88,925 New
PHP
34
Parkman Healthcare Partners
Connecticut
$1.25M -$708K -62,322 -42%
Geode Capital Management
35
Geode Capital Management
Massachusetts
$1.16M +$352K +31,017 +62%
PA
36
Perceptive Advisors
New York
$1.12M +$896K +78,811 New
Manulife (Manufacturers Life Insurance)
37
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$1.1M +$207K +18,190 +31%
Royal Bank of Canada
38
Royal Bank of Canada
Ontario, Canada
$998K +$723K +63,594 +978%
CCM
39
Connective Capital Management
California
$829K +$661K +58,189 New
HP
40
HealthInvest Partners
Sweden
$824K +$657K +57,847 New
Renaissance Technologies
41
Renaissance Technologies
New York
$768K +$612K +53,900 New
NM
42
NWI Management
New York
$764K -$1.22M -107,290 -67%
SVCM
43
Saturn V Capital Management
Texas
$752K +$600K +52,781 New
Morgan Stanley
44
Morgan Stanley
New York
$720K +$295K +25,981 +106%
State Street
45
State Street
Massachusetts
$712K -$4.38K -385 -0.8%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$701K +$559K +49,203 New
ACP
47
Altitude Crest Partners
Connecticut
$614K +$490K +43,100 New
SSA
48
Sierra Summit Advisors
Nevada
$530K +$423K +37,237 New
Bank of America
49
Bank of America
North Carolina
$523K +$412K +36,233 +7,247%
FAM
50
Fred Alger Management
New York
$468K +$374K +32,886 New
1
2
3 4

AMAM Hedge Fund Activity: Q4 2023 in Review

68 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q4 2023, worth a combined $913M — up 61% from $568M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new AMAM positions and 9 closed out — a net gain of 25 holders — while 19 added to existing stakes and 13 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $42.2M. The largest seller was Commodore Capital, exiting entirely with an estimated $40.5M sold.

  • 68 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q4 2023, up from 44 in Q3 2023.
  • Funds reported $913M of Ambrx Biopharma Inc stock for Q4 2023, up 61% quarter-over-quarter.
  • 34 funds opened new Ambrx Biopharma Inc positions in Q4 2023 and 9 closed out, a net change of +25 holders.
  • The largest Ambrx Biopharma Inc buyer in Q4 2023 was Deep Track Capital, an estimated $42.2M added.
  • The largest Ambrx Biopharma Inc seller in Q4 2023 was Commodore Capital, an estimated $40.5M sold.

Based on aggregated 13F filings for Q4 2023.